Integra LifeSciences (NASDAQ:IART) Trading Down 11.9% - Time to Sell?

Key Points

• Integra LifeSciences' stock price dropped 11.9% to $11.58, down from a previous close of $13.14, with trading volume decreasing by 37% from its average.
• Several analysts have reduced their price targets for the stock, with Wells Fargo lowering it from $25.00 to $13.00 and JPMorgan from $24.00 to $12.00, leading to a consensus rating of "Hold."
• Despite beating earnings expectations with a reported $0.45 EPS, Integra's revenue was down 0.6% year-over-year, highlighting ongoing operational challenges.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report)'s share price traded down 11.9% on Friday . The stock traded as low as $11.64 and last traded at $11.58. 613,484 shares were traded during mid-day trading, a decline of 37% from the average session volume of 980,313 shares. The stock had previously closed at $13.14.

Wall Street Analysts Forecast Growth

IART has been the topic of several analyst reports. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. JMP Securities reduced their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company reduced their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Trading Up 1.9%

The company has a market cap of $994.22 million, a P/E ratio of -1.96, a PEG ratio of 0.69 and a beta of 1.16. The stock's 50 day moving average is $12.60 and its 200-day moving average is $17.51. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm had revenue of $415.61 million during the quarter, compared to analyst estimates of $395.06 million. During the same quarter in the prior year, the firm earned $0.63 EPS. The business's revenue for the quarter was down .6% compared to the same quarter last year. Research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its holdings in Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after acquiring an additional 1,371 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Integra LifeSciences by 205.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company's stock valued at $38,000 after acquiring an additional 2,108 shares during the last quarter. Sterling Capital Management LLC boosted its position in shares of Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after acquiring an additional 1,931 shares during the last quarter. AlphaQuest LLC bought a new position in shares of Integra LifeSciences during the 2nd quarter valued at approximately $73,000. Finally, CWM LLC boosted its position in shares of Integra LifeSciences by 32.6% during the 2nd quarter. CWM LLC now owns 8,834 shares of the life sciences company's stock valued at $108,000 after acquiring an additional 2,170 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.